A federal appeals court in Philadelphia ruled 3-0 this morning that “Congress never said that drug makers must deliver discounted Section 340B drugs to an unlimited number of contract pharmacies.”
“By trying to enforce that supposed requirement, the government overstepped the statute’s bounds,” a three-judge panel of the U.S. Third Circuit Court of Appeals held Jan. 30 in drug manufacturers’ AstraZeneca, Sanofi, and Novo Nordisk’s lawsuits challenging the legality of federal 340B program violation determinations against them.
A federal appeals court in Philadelphia ruled 3-0 this morning that “Congress never said that drug makers must deliver discounted Section 340B drugs to an unlimited number of contract pharmacies.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
